Fig. 2: rhIL-7-hyFc has a superior function for HSC mobilization than G-CSF and synergizes with G-CSF and AMD3100.

a, b Mobilization of HSCs by a single dose of rhIL-7-hyFc (2.5 mg/kg) or PEG-rhG-CSF (250 μg/kg), or a repeated dose of rhG-CSF (bidaily 312.5 μg/kg/day for 4 consecutive days). Experimental scheme (a). Representative dot plot and numbers of PB HSCs (n = 10) and CFU-GM (rhIL-7-hyFc; n = 8, other groups; n = 7) (b). c, d Competitive reconstituting assay with peripheral blood mononuclear cells (PBMCs) isolated from rhIL-7-hyFc or PEG-rhG-CSF-treated mice (CD45.2⁺) and BM competitor cells (CD45.1⁺). Blood chimerism in leukocytes at 8, 12, and 18 weeks (c) and in lineage cells at 8 weeks (d) (n = 5). e Mobilization of HSCs by control, 2.5 mg/kg rhIL-7-hyFc, or combination with 250 μg/kg PEG-rhG-CSF and 5 mg/kg AMD3100 (control; n = 4, other groups; n = 5). f-i Combined treatment with 0.5 mg/kg rhIL-7-hyFc, 250 μg/kg PEG-rhG-CSF, and 5 mg/kg AMD3100. Experimental scheme (f) and numbers of PB HSCs (g–i) (n = 13, 10, and 11 for g, h, and i, respectively). Data are pooled from two independent experiments (b, g-i, mean ± SEM) and are representative of 2 or 3 independent experiments (c–e, mean ± SD). P values were determined by one-way ANOVA with Tukey’s multiple comparison for (b), (e), (g-i), two-way ANOVA with Bonferroni’s multiple comparison for (c), and unpaired t test for (d). “n” indicates the sample number. *P < 0.05, **P < 0.01, ***P < 0.001.